Fianlimab and Cemiplimab as Total Neoadjuvant Therapy (TNT) For Melanoma
University of California, Irvine
Summary
This is a phase II, open label clinical trial determining efficacy of Fianlimab in combination with Cemiplimab in subjects with Melanoma. These are subjects who will have surgery to remove their cancer.
Eligibility
- Age range
- Not specified
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * ≥18 years at the time of signing informed consent form (ICF) and able to independently complete informed consent. A certified translator must be used in the completion of informed consent for non-English speaking individuals. * Patients must have surgically resectable, macroscopic Stage IIIB-D cutaneous melanoma or oligometastatic resectable stage IV (M1a, M1b, and M1c) melanoma per American Joint Committee on Cancer 8th Edition Staging Criteria. Patients are eligible at the time of the initial diagnosis or recurrence after previous surgery. Patients should have \> 1 REC…
Interventions
- DrugFianlimab
Given IV
- DrugCemiplimab
Given IV
Location
- Chao Family Comprehensive Cancer Center University of California, IrvineOrange, California